Classification
Epidemiology
Prognosis
Chemotherapy
Targeted therapy
Author (year) | Agent | Phase | Line | Number | ORR (%) | PFS | OS |
---|---|---|---|---|---|---|---|
Agents targeting the EGFR pathway | |||||||
Philip (2006) [42] | Erlotinib | II | 1st/2nd | 42 | 8 | 2.6 months | 7.5 months |
Lee (2012) [44••] | GemOx/erlotinib vs. GemOx | III | 1st | 135 vs. 133 | 30 vs. 16 | 5.8 vs. 4.2 months | 9.5 vs. 9.5 months |
Gruenberger (2010) [45] | GemOx/cetuximab | II | 1st | 30 | 63 | 8.8 months | 15.2 months |
Malka (2014) [46•] | GemOx/cetuximab vs. GemOx | II | 1st | 76 vs. 74 | 24 vs. 23 | 6.1 vs. 5.5 months | 11.0 vs. 12.4 months |
Chen (2015) [47•] | GemOx/cetuximab vs. GemOx | II | 1st | 62 vs. 60 | 27 vs. 15 | 6.7 vs. 4.1 months | 10.6 vs. 9.8 months |
Rubovszky (2013) [48] | Gem/Cape/cetuximab | II | 1st | 34 | 18 | 34.3 weeks | 62.8 weeks |
Hezel (2014) [49] | GemOx/panitumumab | II | 1st | 31 | 45 | 10.6 months | 20.3 months |
Leone (2015) [50] | GemOx/panitumumab vs. GemOx | II | 1st | 45 vs. 44 | 24.4 vs. 18.2 | 7.7 vs. 5.5 months | 9.5 vs. 9.9 months |
Jensen (2012) [51] | GemOx/Cape/panitumumab | II | 1st | 46 | 33 | 8.3 months | 10.0 months |
Sohal (2013) [52] | Gem/Irino/panitumumab | II | 1st | 35 | 69 | 9.7 months | 12.9 months |
Agents targeting the EGFR/HER2 pathway | |||||||
Ramanathan (2009) [56] | Lapatinib | II | 1st/2nd | 17 | 0 | 1.8 months | 5.2 months |
Agents targeting the VEGF pathway | |||||||
Zhu (2010) [59] | GemOx/bevacizumab | II | 1st/2nd | 35 | 40 | 7.0 months | 12.7 months |
Iyer (2015) [60] | Gem/Cape/bevacizumab | II | 1st | 50 | 24 | 8.1 months | 11.3 months |
Valle (2014) [63•] | GemCis/cediranib vs. GemCis/placebo | II | 1st | 62 vs. 62 | 43 vs. 19 | 7.7 vs. 7.4 months | 14.1 vs. 11.9 months |
Bengala (2010) [66] | Sorafenib | II | Any | 46 | 2 | 2.3 months | 4.4 months |
El-Khoueiry (2012) [67] | Sorafenib | II | 1st | 31 | 0 (6 % unconfirmed PR) | 3 months | 9 months |
Moehler (2014) [68] | Gem/sorafenib vs. Gem/placebo | II | 1st | 52 vs. 50 | 14 vs. 10 | 3.0 vs. 4.9 months | 8.4 vs. 11.2 months |
Lee (2013) [70] | GemCis/sorafenib | II | 1st | 39 | 12 | 6.5 months | 14.4 months |
Krege (2014) [69] | GemCis/sorafenib vs. GemCis/placebo | II | 1st | 40 vs. 49 | 52.5 vs. 47 | 6.3 vs. 6.1 months | 11.3 vs. 10.6 months |
Yi (2012) [72] | Sunitinib | II | 2nd | 56 | 8.9 | 1.7 months | 4.8 months |
Agents targeting the EGFR/VEGF pathway | |||||||
Lubner (2010) [43] | Bevacizumab/erlotinib | II | 1st | 53 | 12 | 4.4 months | 9.9 months |
Santoro (2015) [73] | Vandetanib vs. Gem/vandetanib vs. Gem/placebo | II | 1st | 59 vs. 58 vs. 56 | 3.6 vs. 19.3 vs. 13.5 | 105 vs. 114 vs. 148 days | 228 vs. 284 vs. 307 days |
Agents targeting the MEK pathway | |||||||
Bekaii-Saab (2011) [78] | Selumetinib | II | 1st/2nd | 28 | 12 | 3.7 months | 9.8 months |
Finn (2012) [79] | Binimetinib | I | 1st/2nd | 28 | 8 | NR | NR |
Lowery (2015) [80] | GemCis/binimetinib | I | 1st | 12 | 50 | 6.4 months | 9.1 months |
Agents targeting the mTOR pathway | |||||||
Buzzoni (2014) [84] | Everolimus | II | 2nd | 39 | 5.1 | 3.2 months | 7.7 months |
Yeung (2014) [85] | Everolimus | II | 1st | 27 | 12 | 6.0 months | 9.5 months |
ErbB family signaling pathway
Drug | Class | Phase | Arms | NCT number |
---|---|---|---|---|
Cetuximab | EGFR antibody | II | Gemcitabine + oxaliplatin with or without cetuximab | NCT01267344 |
Afatinib | EGFR inhibitor | I | Cisplatin + gemcitabine + afatinib (single arm) | NCT01679405 |
Cediranib | VEGF inhibitor | II | FOLFOX with cediranib (single arm) | NCT01229111 |
Regorafenib | Multikinase inhibitor | II | Regorafenib (single arm) | NCT02053376 |
Regorafenib | Multikinase inhibitor | I/II | Gemcitabine + oxaliplatin + regorafenib (single arm) | NCT02386397 |
Regorafenib | Multikinase inhibitor | II | Regorafenib (single arm) | NCT02053376 |
Regorafenib | Multikinase inhibitor | II | Regorafenib (single arm) | NCT02115542 |
Ponatinib | Multikinase inhibitor | II | Ponatinib (single arm) | NCT02265341 |
Pazopanib | Multikinase inhibitor | II | Pazopanib (single arm) | NCT01855724 |
Pazopanib | Multikinase inhibitor | II | Pazopanib + gemcitabine (single arm) | NCT01855724 |
Trametinib | MEK inhibitor | II | Trametinib vs. 5-FU | NCT02042443 |
Trametinib | MEK inhibitor | II | Trametinib (single arm) | NCT01943864 |
Selumitinib | MEK inhibitor | II | Cisplatin + gemcitabine with or without selumitinib | NCT02151084 |
Binimetinib | MEK inhibitor | I/II | Cisplatin + gemcitabine + binimetinib (single arm) | NCT01828034 |
Vismodegib | Hh pathway inhibitor | I | Vismodegib (single arm) | NCT00968981 |
RO4929097 | Notch inhibitor | I | RO4929097 (single arm) | NCT01096355 |
BGJ 398 | FGFR inhibitor | II | BGJ 398 (single arm) | NCT02150967 |
Ponatinib | FGFR inhibitor | II | Ponatinib (single arm) | NCT02265341 |
AG-881 | IDH inhibitor | I | AG 881 (single arm) | NCT02481154 |
AG-120 | IDH inhibitor | I | AG-120 (single arm) | NCT02073994 |